Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | MPL | P40238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21006718 | 1.00 | OGA (0.40) | OGADYRK1ASLC2A1CCR2ACHE | |
| SCHEMBL18724113 | 0.97 | OGA (0.40) | OGADYRK1ASLC2A1CCR2ACHE | |
| SCHEMBL21005881 | 0.97 | OGA (0.40) | OGADYRK1ASLC2A1CCR2ACHE | |
| SCHEMBL18724239 | 0.91 | GRM2 (0.37) | OGADYRK1ACCR2ACHETRPA1 | |
| SCHEMBL21005961 | 0.91 | OGA (0.40) | OGADYRK1ASLC2A1ACHE | |
| SCHEMBL17412757 | 0.91 | CRHR1 (0.41) | OGADYRK1AACHEMPL | |
| SCHEMBL18724037 | 0.91 | OGA (0.40) | OGADYRK1ASLC2A1ACHE | |
| SCHEMBL30440610 | 0.91 | CRHR1 (0.41) | OGADYRK1AACHEMPL | |
| SCHEMBL18724357 | 0.91 | CRHR1 (0.37) | OGADYRK1AACHETRPA1TRPV4 | |
| SCHEMBL21006189 | 0.90 | OGA (0.39) | OGADYRK1ASLC2A1CCR2MPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110845490-B | 2-acylaminothiazole derivative or salt thereof | 旭飞药业股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-RE49111-E1 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-RE49111-E1 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2022-06-21 | — | — | US | disclosed |
| CN-106573928-B | 2-aminothiazole derivative or salt thereof | 安斯泰来制药株式会社 | 2020-04-14 | — | — | CN | disclosed |
| CN-110845490-A | 2-acylaminothiazole derivative or salt thereof | 安斯泰来制药株式会社 | 2020-02-28 | — | — | CN | disclosed |
| CN-106414438-B | 2-acylaminothiazole derivative or salt thereof | 安斯泰来制药株式会社 | 2019-12-31 | — | — | CN | disclosed |
| EP-2963036-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2019-08-28 | — | — | EP | disclosed |
| EP-2963036-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2019-08-28 | — | — | EP | disclosed |
| EP-3153511-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES | ASTELLAS PHARMA INC (JP) | 2019-05-15 | — | — | EP | disclosed |
| EP-3153511-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES | ASTELLAS PHARMA INC (JP) | 2019-05-15 | — | — | EP | disclosed |
| US-20170197955-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| CN-106573928-A | 2-aminothiazole derivative or salt thereof | 安斯泰来制药株式会社 | 2017-04-19 | — | — | CN | disclosed |
| EP-3153511-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2017-04-12 | — | — | EP | disclosed |
| EP-3153511-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-9562044-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9562044-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2963036-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | Astellas Pharma Inc. (JP) | 2016-01-06 | — | — | EP | disclosed |
| EP-2963036-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | Astellas Pharma Inc. (JP) | 2016-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, CHRM5 | OGA 2832/4885DYRK1A 2063/4885SLC2A1 3126/4885 |
| US-20170197955-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, TRPM2 | OGA 2438/4885DYRK1A 2029/4885SLC2A1 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.